Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study by Hector Gonzalez Dorta, MSc, Johan Verbeeck, PhD, Jonas Crevecoeur, PhD, Daniel R Morales, PhD, Neilshan Loedy, MSc, Catherine Cohet, PhD, Lander Willem, PhD, Geert Molenberghs, ProfPhD, Niel Hens, ProfPhD, Xavier Kurz, PhD, Chantal Quinten, PhD, Steven Abrams, PhD

Get full text